2022
Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 670-679. PMID: 35614009, DOI: 10.1016/j.clml.2022.04.016.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHMA therapyPoor performance statusRate of hospitalizationSEER-Medicare databaseMyelodysplastic syndromeER visitsEarly discontinuationPerformance statusEmergency roomOlder agePredictors of discontinuationEmergency room visitsHigh-risk groupHigh economic burdenTreatment discontinuationExcess blastsMore hospitalizationsNew hospitalizationRefractory anemiaRoom visitsHigh riskDiscontinuationMD diagnosisAgent use
2021
Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes. Journal Of Clinical Oncology 2021, 39: 7043-7043. DOI: 10.1200/jco.2021.39.15_suppl.7043.Peer-Reviewed Original ResearchPoor performance statusPoor PSHigh-risk myelodysplastic syndromeHMA therapyReal-world studyMyelodysplastic syndromeProgression/unacceptable toxicityPills/dayRetrospective cohort studyTreatment-related factorsMultivariable logistic regressionDirect medical costsHigh-risk groupOne-thirdGCSF useMore comorbiditiesEarly discontinuationPerformance statusUnacceptable toxicityCohort studyExcess blastsMultivariable analysisRefractory anemiaSEER-MedicareSurvival outcomes
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens
2012
Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 3837. DOI: 10.1182/blood.v120.21.3837.3837.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTransfusion independenceTransfusion useMyelodysplastic syndromeRisk groupsTransfusion statusLens useObservational studyClaims dataLarge population-based observational studiesResponse rateIntermediate-risk myelodysplastic syndromesPopulation-based observational studyICD-9-CM codesCycles of therapyInitiation of lenalidomidePoor performance statusReceipt of transfusionClinical trial evidenceInitiation of treatmentAge 75 yearsTransfusion-dependent anemiaEnd of studyZIP Code-level measuresMedicare Part A